Gemzar Ovarian Cancer Negative Review Shows Discomfort With Ex-U.S. Data
The Oncologic Drugs Advisory Committee's negative review of Lilly's Gemzar for treatment of ovarian cancer illustrates the difficulty of receiving approval for submissions based on solely ex-U.S. trials lacking FDA input on design
You may also be interested in...
Progression-free survival will have to be validated as a surrogate for survival on a cancer-by-cancer basis for PFS to be considered as a valid endpoint for approval, comments by FDA and members of its Oncologic Drugs Advisory Committee suggest
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011